# Clinical Trial on Depression Treatment (PoET Study)



A relatively new molecule is being used to treat depression. It is administered via a nasal spray and will be used alongside well-established antidepressant treatments in the management of depression.

### **Study Aims**

- 1. To identify patients that respond to the trial drug
- 2.Determine when to use the trial drug in clinical practice

## Referral & Enrolment

 To enrol a patient in the study, please complete the referral form available at <u>www.cadeclinic.com/poetstudy</u>

### Inclusion Criteria

- Adults:
  - 18 65 years old
  - Primary diagnosis of major depression
  - Currently depressed and on medication
  - Inadequate response to 2 or more antidepressants during current depressive episode

### **Exclusion Criteria**

#### 1. Treatments

- Patients on complementary and alternative medicine therapies
- Once the referral is received, one of our research staff will contact your patient to screen them for enrolment

#### Contacts

- Trial Coordinator: Uyen Le
  - <u>NSLHD-researchpoet@health.nsw.gov.au</u>
  - (O2) 9463 1656
  - Availability: Monday-Friday
    - 10am-3pm







NSLHD Research Contact: NSLHD-Research@health.nsw.gov.au REGIS ID: 2023/STE02155  Patients with hypersensitivity to Esketamine, Ketamine, or any of the excipients in these formulations

#### 2. Disorders

- a. Psychiatric
  - Patients with psychiatric disorders e.g., schizophrenia, bipolar, substance misuse
- b. Vascular
  - Uncontrolled hypertension
  - Thoracic and abdominal aorta
  - Intracranial and peripheral arterial vessels arteriovenous malformation
  - Intracerebral haemorrhage

#### 3. Pregnancy

- Patients who are pregnant or breastfeeding
- Patients who are not willing to avoid pregnancy for themselves or their partners during the study by using effective birth control methods



Visit our page: www.cadeclinic.com/poetstudy